Zobrazit v EDS

Cellular Bone Matrix in Spine Surgery – Are They Worth the Risk: A Systematic Review.

Uloženo v:
Podrobná bibliografie
Název: Cellular Bone Matrix in Spine Surgery – Are They Worth the Risk: A Systematic Review.
Autoři: Lambrechts, Mark J., Issa, Tariq Z., Mazmudar, Aditya, Lee, Yunsoo, Toci, Gregory R., D'Antonio, Nicholas D., Schilken, Meghan, Lingenfelter, Kenneth, Kepler, Christopher K., Schroeder, Gregory D., Vaccaro, Alexander R.
Zdroj: Global Spine Journal; Apr2024, Vol. 14 Issue 3, p1070-1081, 12p
Témata: SPINAL surgery, SPINAL fusion, CERVICAL vertebrae, LUMBAR vertebrae, DATABASES, REOPERATION
Abstrakt: Study Design: Systematic Review. Objective: To review the literature for complications and outcomes after the implantation of cellular bone matrix (CBM) during spine fusion. Methods: The PubMed database was queried from inception to January 31, 2023 for any articles that discussed the role of and identified a specific CBM in spinal fusion procedures. Adverse events, reoperations, methods, and fusion rates were collected from all studies and reported. Results: Six hundred articles were identified, of which 19 were included that reported outcomes of 7 different CBM products. Seven studies evaluated lumbar fusion, 11 evaluated cervical fusion, and 1 study reported adverse events of a single CBM product. Only 4 studies were comparative studies while others were limited to case series. Fusion rates ranged from 68% to 98.7% in the lumbar spine and 87% to 100% in the cervical spine, although criteria for radiographic fusion was variable. While 7 studies reported no adverse events, there was no strict consensus on what constituted a complication. One study reported catastrophic disseminated tuberculosis from donor contaminated CBM. The authors of 14 studies had conflicts of interest with either the manufacturer or distributor for their analyzed CBM. Conclusions: Current evidence regarding the use of cellular bone matrix as an osteobiologic during spine surgery is weak and limited to low-grade non-comparative studies subject to industry funding. While reported fusion rates are high, the risk of severe complications should not be overlooked. Further large clinical trials are required to elucidate whether the CBMs offer any benefits that outweigh the risks. [ABSTRACT FROM AUTHOR]
Copyright of Global Spine Journal is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Complementary Index
Popis
Abstrakt:Study Design: Systematic Review. Objective: To review the literature for complications and outcomes after the implantation of cellular bone matrix (CBM) during spine fusion. Methods: The PubMed database was queried from inception to January 31, 2023 for any articles that discussed the role of and identified a specific CBM in spinal fusion procedures. Adverse events, reoperations, methods, and fusion rates were collected from all studies and reported. Results: Six hundred articles were identified, of which 19 were included that reported outcomes of 7 different CBM products. Seven studies evaluated lumbar fusion, 11 evaluated cervical fusion, and 1 study reported adverse events of a single CBM product. Only 4 studies were comparative studies while others were limited to case series. Fusion rates ranged from 68% to 98.7% in the lumbar spine and 87% to 100% in the cervical spine, although criteria for radiographic fusion was variable. While 7 studies reported no adverse events, there was no strict consensus on what constituted a complication. One study reported catastrophic disseminated tuberculosis from donor contaminated CBM. The authors of 14 studies had conflicts of interest with either the manufacturer or distributor for their analyzed CBM. Conclusions: Current evidence regarding the use of cellular bone matrix as an osteobiologic during spine surgery is weak and limited to low-grade non-comparative studies subject to industry funding. While reported fusion rates are high, the risk of severe complications should not be overlooked. Further large clinical trials are required to elucidate whether the CBMs offer any benefits that outweigh the risks. [ABSTRACT FROM AUTHOR]
ISSN:21925682
DOI:10.1177/21925682231205099